AMSBIO offers a wide range of small molecules to provide scientists with targeted tools to direct cell fates, making them crucial in areas including regenerative medicine and cancer research. 

Small molecules are cell-permeable organic compounds with low molecular weights, which are chemically produced, in contrast to larger molecules such as proteins which are often produced via biological means. Small molecules are crucial components of an affordable cell culture toolkit that can be used to maintain, reprogram, and differentiate cells.

  • Capivasertib alongside hormone therapy doubles time before advanced breast cancer progresses

  • Combination set to become new treatment option for patients with advanced forms of most common type of breast cancer

  • Inhibitor of cancer-driving protein AKT shows broad benefits in patients with ER positive, HER2 negative breast cancer

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial.

Agreements build on Sosei Heptares’ Target Identification and Validation strategy and translational medicine approach to drug discovery, enabling the Company to rapidly prioritize disease-relevant GPCR targets for structure-based drug design

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces a selection of new contract wins where Optimer technology is being explored by partners to offer new strategies for therapeutics and potentially offer improved assay sensitivity and selectivity over antibodies.

Click here to view the November edition of The Meeting Place

Welcome to the Autumn edition of BioBrief, our quarterly newsletter providing essential updates and analysis for those working in the life sciences sector.

In this edition you will find:

AMSBIO has published an informative handbook for scientists who need to preserve or archive organoids in a research lab.

The handbook brings together published paper citations, quotes and data from leading international research groups who are using the CELLBANKER® range of products to cryopreserve their organoids simply and safely. In addition, the handbook includes best practice protocols plus information making it easier to understand the process of freezing organoids and to choose the optimum cryopreservation media for your application.

Arecor Therapeutics plc

(“Arecor” or the “Group”)


Clinical Trial Application approved

EU Phase I clinical trial expected to commence in December 2022

The granted patents further strengthen the Group’s extensive patent portfolio protecting its proprietary Arestat™ technology and diabetes product portfolio

Cambridge, UK, 22 November 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce that the Japan Patent Office has granted a patent (JP7145849) protecting novel formulations of the Group’s proprietary insulin products, AT247 and AT278. The same patent has also been granted in South Korea.